FDA grants breakthrough therapy designation to Lilly’s olomorasib

Olomorasib is an investigational inhibitor targeting the KRAS G12C protein, under study for various solid tumours. Credit: Sai Thaw Kyar / Shutterstock.com.



  • FDA Lilly olomorasib